Kisspeptin-10
Kisspeptin-10 is the ten-amino-acid C-terminal fragment of kisspeptin studied in reproductive hormone signaling.
The short version
- Why people discuss it
- Discussed for libido, reproductive-hormone signaling and fertility-related goals. Community interest does not establish benefit or a suitable treatment.
- What it is
- Kisspeptin-10 is the ten-amino-acid C-terminal fragment of kisspeptin studied in reproductive hormone signaling.
- Biggest caution
- Monitored reproductive-endocrine studies do not establish a general fertility, testosterone or sexual-health regimen. Timing, population, route and desensitization questions are product-specific.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 100–200 mcg
- Frequency
- Every other day
- Duration / phase
- 4–8 weeks
Legacy kisspeptin-10 community example. The new source gives daily 100–200 mcg but does not specify the form. Kisspeptin-54 clinical research cannot verify this kisspeptin-10 schedule. Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
100→200 mcg SC daily for 8–12 weeks, but form unspecified.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27